Welcome to our Free Content Page
The Medical Letter, Inc. is a nonprofit organization--we accept no grants, donations or advertising. We are supported entirely by sales of our subscriptions, handbooks and software. If you value the balanced truth, and wish to ensure your continued access to this impartial source of drug information, please subscribe today.   
The Medical Letter on Drugs and Therapeutics • October 23, 2017 (Issue 1532)
In our article on Drugs for Cognitive Loss and Dementia (Med Lett Drugs Ther 2017; 59:155), the last sentence at the end of the article should have been omitted. It has been deleted from the article online.
The Medical Letter on Drugs and Therapeutics • October 9, 2017 (Issue 1531)
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
The Medical Letter on Drugs and Therapeutics • October 9, 2017 (Issue 1531)
Pancreatic enzyme replacement products have been used for years to improve digestion in patients with exocrine pancreatic insufficiency (EPI). These products were initially marketed before formal FDA approval was required; in 1991, however, the FDA told all manufacturers of pancreatic enzyme replacement products that they would have to submit a new drug application by April 2010 in order to keep...
The Medical Letter on Drugs and Therapeutics • September 11, 2017 (Issue 1529)
The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA). Also called dehydroepiandrosterone (DHEA), prasterone is produced in the adrenal glands, gonads, and brain and converted intracellularly into active metabolites of estrogens and androgens. DHEA has...
The Medical Letter on Drugs and Therapeutics • September 11, 2017 (Issue 1529)
In Table 3 on page 116 (Med Lett Drugs Ther 2017; 59:113), the price provided for Prevpac was for a 14-day supply, rather than for a 10-day supply as stated in footnote 1. The footnote has been corrected and the price of the generic formulation of Prevpac has been added.
The Medical Letter on Drugs and Therapeutics • August 14, 2017 (Issue 1527)
The FDA has approved the oral multikinase inhibitor midostaurin (Rydapt – Novartis) for first-line treatment, in addition to standard chemotherapy, of adults with FLT3 (fms-like tyrosine kinase 3) mutation-positive acute myeloid leukemia (AML). About 30% of patients with AML have FLT3 mutations. Midostaurin is also approved as a single agent for treatment of adults with aggressive...
The Medical Letter on Drugs and Therapeutics • July 17, 2017 (Issue 1525)
The FDA has approved the fully-human programmed death ligand 1 (PD-L1) blocking antibody avelumab (Bavencio – EMD Serono/Pfizer) for treatment of metastatic Merkel cell carcinoma (MCC) in patients ≥12 years old. Avelumab is the first drug to be approved in the US for this rare skin cancer. About 1600 people in the US, most commonly older adults (mean age at presentation is 75 years), are...
The Medical Letter on Drugs and Therapeutics • June 5, 2017 (Issue 1522)
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the CDC, there were 33,091 deaths related to opioid overdose in the US in 2015, more...
The Medical Letter on Drugs and Therapeutics • June 5, 2017 (Issue 1522)
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • May 22, 2017 (Issue 1521)
Per capita spending on prescription drugs in the US is higher than in other industrialized nations, including Canada.
The Medical Letter on Drugs and Therapeutics • May 8, 2017 (Issue 1520)
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma.

H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis...
The Medical Letter on Drugs and Therapeutics • April 24, 2017 (Issue 1519)
The FDA has warned that eluxadoline (Viberzi – Allergan), a mu-opioid receptor agonist and delta-opioid receptor antagonist approved in 2015 for treatment of irritable bowel syndrome with diarrhea (IBS-D),1 should not be used in patients without a gallbladder because of an increased risk of serious pancreatitis.2...
The Medical Letter on Drugs and Therapeutics • April 24, 2017 (Issue 1519)
The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations.1 The complete schedule is available on the CDC's website (www.cdc.gov/vaccines/schedule). New recommendations for use of influenza...
The Medical Letter on Drugs and Therapeutics • February 13, 2017 (Issue 1514)
An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of a triptan early in an attack when pain is still mild to moderate in intensity improves headache response and reduces recurrence rates.
The Medical Letter on Drugs and Therapeutics • January 30, 2017 (Issue 1513)
Drugs for Diabetes (Med Lett Drugs Ther 2017; 59:9)
In the 4th paragraph of the GLP-1 receptor agonists section, we mistakenly stated that Xultophy 100/3.6 is a combination of insulin degludec and albiglutide; Xultophy 100/3.6 is a combination of insulin degludec and liraglutide.

Another...
The Medical Letter on Drugs and Therapeutics • December 5, 2016 (Issue 1509)
Therapeutics (AZCERT) has recently added the proton pump inhibitors (PPIs) omeprazole (Prilosec, and others), esomeprazole (Nexium, and others), lansoprazole (Prevacid, and others), and pantoprazole (Protonix, and generics) to its lists of Drugs with Conditional Risk of Torsades de Pointes (TdP) and Drugs to Avoid in Patients with Congenital Long QT Syndrome....
The Medical Letter on Drugs and Therapeutics • December 5, 2016 (Issue 1509)
The FDA has approved Lomaira (KVK Tech), an 8-mg tablet formulation of phentermine that can be taken up to three times daily before meals, as an adjunct to lifestyle modifications for weight loss. It is only approved for short-term use (a few weeks) in adults with a body mass index (BMI) ≥30 kg/m2, or with a BMI ≥27 kg/m2 in addition to a weight-related comorbidity...
The Medical Letter on Drugs and Therapeutics • December 5, 2016 (Issue 1509)
In our recent article on Lipid-Lowering Drugs,1 we said that statins can reduce the risk of first cardiovascular events and death (primary prevention) in patients at high risk for atherosclerotic cardiovascular disease (CVD) and significantly reduce the incidence of cardiovascular events in patients at lower risk for CVD. Now the United States Preventive...
The Medical Letter on Drugs and Therapeutics • November 21, 2016 (Issue 1508)
Head lice infestation occurs in all age groups, but especially in elementary school children. In most cases, transmission occurs by head-to-head contact.
The Medical Letter on Drugs and Therapeutics • November 7, 2016 (Issue 1507)
The oral biguanide metformin (Glucophage, and others) is generally the drug of choice for initial treatment of type 2 diabetes. It has also been used to prevent or at least delay the onset of diabetes in patients considered to be at high risk for the disease. Recent guidelines recommend considering use of metformin in patients with prediabetes (fasting plasma glucose 100-125 mg/dL, 2-hr...